Sepsis 2026 guidelines summary
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive content from multiple authoritative textbooks — Harrison's 22nd Edition (2025), Current Surgical Therapy 14e, Rosen's Emergency Medicine, Sabiston Surgery, and others. Let me compile a thorough summary.
Sepsis: Current Guidelines Summary (Surviving Sepsis Campaign 2021 + Sepsis-3)
Sourced from Harrison's Principles of Internal Medicine 22E (2025), Current Surgical Therapy 14e, Rosen's Emergency Medicine, Sabiston Textbook of Surgery, and Mulholland & Greenfield's Surgery.
1. Definitions (Sepsis-3, 2016 — Still Current)
| Term | Definition |
|---|---|
| Sepsis | Life-threatening organ dysfunction caused by a dysregulated host response to infection |
| Organ dysfunction | SOFA score increase ≥2 points from baseline |
| Septic shock | Sepsis + vasopressor requirement to maintain MAP ≥65 mmHg AND serum lactate >2 mmol/L despite adequate fluid resuscitation |
The prior terms "SIRS" and "severe sepsis" were eliminated by Sepsis-3 to reduce excessive focus on inflammation.
2. Screening Tools
SOFA Score (Sequential Organ Failure Assessment)
Used to confirm organ dysfunction. Domains:
| System | Parameter |
|---|---|
| Respiratory | PaO₂/FiO₂ ratio |
| Coagulation | Platelets |
| Liver | Bilirubin |
| Cardiovascular | MAP / vasopressor requirement |
| CNS | Glasgow Coma Scale |
| Renal | Creatinine |
A rise of ≥2 points = organ dysfunction consistent with sepsis.
qSOFA (Quick SOFA)
Rapid bedside screening tool (does not confirm sepsis alone):
- Respiratory rate ≥22 breaths/min
- GCS <15
- Systolic BP ≤100 mmHg
≥2 of 3 criteria = high risk; warrants full evaluation.
3. Diagnosis
No single gold-standard test exists. Workup should include:
- CBC with differential — leukocytosis, bandemia, thrombocytopenia
- BMP/CMP — lactate, creatinine, bicarbonate, electrolytes
- LFTs, coagulation panel (PT/aPTT, fibrinogen, D-dimer for DIC)
- Blood cultures ×2 (ideally before antibiotics)
- Cultures from other suspected sites (urine, sputum, wound)
- Serum lactate — key prognostic and diagnostic marker
- Imaging (CXR, CT, US) to identify source
Sepsis mimics to rule out: heart failure, COPD exacerbation, mesenteric ischemia, connective tissue disease, adrenal insufficiency, pulmonary embolism (~25% of ICU "sepsis" cases are retrospectively mimics).
4. Initial Management — The Hour-1 Bundle (SSC 2021)
Perform within 1 hour of recognition:
- Measure lactate — remeasure if initial >2 mmol/L
- Blood cultures before antibiotic administration
- Broad-spectrum antibiotics — administer immediately
- IV crystalloid — 30 mL/kg for hypotension or lactate ≥4 mmol/L
- Vasopressors — if hypotension persists during/after fluids to maintain MAP ≥65 mmHg
5. Fluid Resuscitation
- Crystalloids preferred — Normal saline or lactated Ringer's
- Initial bolus: 30 mL/kg IV crystalloid
- Balanced crystalloids (e.g., LR) increasingly preferred over normal saline to reduce hyperchloremic acidosis
- Avoid albumin as initial resuscitation fluid (can be used as adjunct)
- Reassess fluid responsiveness continuously (dynamic measures: pulse pressure variation, stroke volume variation preferred over static CVP)
- Avoid fluid overload — excessive positive fluid balance associated with worse outcomes
6. Antimicrobial Therapy
- Administer within 1 hour of sepsis/septic shock recognition
- Empiric broad-spectrum coverage targeting most likely pathogens based on clinical context, local resistance patterns, and host factors
- De-escalate based on culture results and clinical improvement (typically 7–10 days total; shorter when possible)
- Combination therapy for septic shock or high-risk pathogens (e.g., empiric anti-MRSA + anti-pseudomonal coverage in appropriate settings)
- Blood cultures before antibiotics — but do not delay antibiotics >45 minutes waiting for cultures
7. Vasopressors
| Agent | Role |
|---|---|
| Norepinephrine | First-line vasopressor |
| Vasopressin | Add-on to reduce norepinephrine dose (0.03–0.04 units/min) |
| Epinephrine | Second-line or adjunct |
| Dopamine | Not recommended as first-line (higher arrhythmia risk) |
| Dobutamine | Used for myocardial depression/low cardiac output states |
Target MAP ≥65 mmHg (individualize to patient history; higher targets in chronic hypertension).
8. Corticosteroids
- Hydrocortisone IV (200 mg/day) recommended in vasopressor-dependent septic shock that is refractory despite adequate fluids and vasopressors
- Do not use corticosteroids if hemodynamic goals are achieved without escalating vasopressors
- Rationale: relative adrenal insufficiency / critical illness–related corticosteroid insufficiency (CIRCI)
- Early tapering is not recommended and may be detrimental
9. Source Control
- Identify and eliminate the source of infection as soon as possible (within 6–12 hours)
- Drain abscesses, debride infected tissue, remove infected devices
- Surgical source control is a core principle — sepsis of surgical origin (e.g., perforated viscus, necrotizing fasciitis) requires prompt operative intervention
10. Ventilatory Support (Sepsis-Associated ARDS)
- Low tidal volume ventilation: 6 mL/kg predicted body weight
- Plateau pressure ≤30 cmH₂O
- Prone positioning ≥12 hours/day for moderate-severe ARDS (PaO₂/FiO₂ <150)
- Conservative oxygen targets: SpO₂ 92–96%
- Avoid routine high-dose steroids for ARDS (separate from septic shock steroids)
11. Additional Supportive Care
| Intervention | Recommendation |
|---|---|
| Blood glucose | Maintain <180 mg/dL; avoid hypoglycemia |
| Red cell transfusion | Threshold Hb <7 g/dL (unless ACS, severe hypoxia) |
| DVT prophylaxis | LMWH preferred; mechanical if anticoagulation contraindicated |
| Stress ulcer prophylaxis | For patients with risk factors (mechanical ventilation, coagulopathy) |
| Nutrition | Early enteral nutrition preferred; avoid prolonged starvation |
| Renal replacement therapy | For AKI with fluid overload, severe acidosis, or refractory electrolyte disturbance |
12. Prognosis
- Worldwide: ~11 million deaths/year attributable to sepsis
- Mortality rises sharply with severity — septic shock mortality >40%
- Lactate clearance (≥10% reduction at 2 hours) is associated with improved outcomes
- ICU admission is standard for septic shock
Key References in these textbooks:
- Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 (Intensive Care Med 2021;47:1181–1247)
- Sepsis-3 Definitions: Singer et al., JAMA 2016;315:801–810
— Harrison's Principles of Internal Medicine 22E (2025), — Current Surgical Therapy 14e, — Rosen's Emergency Medicine, — Sabiston Textbook of Surgery
According to surviving sepsis guidelines 2026
The Surviving Sepsis Campaign 2026 guidelines have not yet been published as of my knowledge cutoff. The most current version remains the SSC 2021 guidelines (Intensive Care Med 2021;47:1181–1247).
The SSC updates its guidelines approximately every 4–5 years:
- 2004 → 2008 → 2012 → 2016 → 2021
A 2026 update may be in development or anticipated, but no published version exists in the medical literature available to me, and the textbooks in this library (including Harrison's 22E, 2025) still reference the 2021 SSC guidelines as the most current.
What I can offer instead:
- Full summary of the SSC 2021 guidelines — which I already provided above
- Notable post-2021 evidence that may inform future updates (e.g., CLASSIC trial on restrictive fluids, VITAMINS trial, ANDROMEDA-SHOCK on peripheral perfusion targets)
- Specific clinical questions within sepsis management where evidence has evolved
Would any of these be helpful?
Give sepsis guidelines summary according to this
Surviving Sepsis Campaign 2026 — Full Guidelines Summary
The document you've shared is the actual SSC 2026 guidelines, published in Intensive Care Medicine (DOI: 10.1007/s00134-026-08361-1), co-led by Prescott & Antonelli, representing 69 panelists from 23 countries. Here is a comprehensive structured summary.
Definitions (unchanged from Sepsis-3)
- Sepsis: Life-threatening acute organ dysfunction due to infection
- Septic shock: Sepsis + circulatory dysfunction conferring higher mortality risk
- Diagnosis is clinical — no single biomarker or test rules it in or out (Statement 5, Good Practice)
Sepsis certainty terminology (new in 2026):
| Term | Meaning |
|---|---|
| Definite | Confirmed; alternative diagnosis very unlikely |
| Probable | Most likely diagnosis; alternative less likely |
| Possible | Moderate suspicion; alternative also likely |
| Unlikely | Low suspicion; alternate diagnosis more likely |
Screening & Early Management
| # | Recommendation | Strength |
|---|---|---|
| 1 | Use a performance improvement program including sepsis screening, SOPs, and quality improvement strategies | Strong |
| 2 | Use a "code sepsis" or "sepsis huddle" protocol | Conditional |
| 3 | Use a sepsis screening tool en route to hospital (ambulance/flight) | Conditional |
| 4 | In hospital, use NEWS, NEWS2, MEWS, or SIRS over qSOFA as single screening tool | Strong (upgraded) |
| 5 | Sepsis is a clinical diagnosis; no single biomarker rules it in or out | Good Practice |
| 6 | Insufficient evidence for novel rapid host response diagnostics | — |
qSOFA is retained as a clinical deterioration alert but has poor sensitivity for sepsis screening.
Blood Cultures & Lactate
| # | Recommendation | Strength |
|---|---|---|
| 7 | Collect blood cultures as soon as possible, ideally before antibiotics | Strong (new) |
| 8 | Measure blood lactate in possible/probable/definite sepsis or septic shock | Conditional (carryover) |
Initial Resuscitation
| # | Recommendation | Strength |
|---|---|---|
| 9 | Sepsis is a medical emergency — begin treatment immediately | Good Practice |
| 10 | Administer ≥30 mL/kg IV crystalloid in first 3 hours for sepsis-induced hypoperfusion or shock | Conditional (revisited) |
| 11 | Initial crystalloid bolus first, then vasopressors if hypotension persists; in unstable shock, concurrent vasopressors may be warranted | Conditional (new) |
| 12 | Start vasopressors peripherally rather than waiting for central access | Conditional (revisited) |
| 13 | Target MAP ≥65 mmHg | Strong (carryover) |
| 14 | In patients ≥65 years: target MAP 60–65 mmHg over higher ranges | Conditional (new) |
| 15 | ICU admission within 6 hours for those requiring it | Conditional (carryover) |
Infection / Antibiotics
Timing
| Scenario | Recommendation | Strength |
|---|---|---|
| Possible, probable, or definite septic shock | Antimicrobials immediately, ideally within 1 hour | Strong |
| Probable or definite sepsis without shock | Antimicrobials immediately, ideally within 1 hour | Strong |
| Possible sepsis without shock | Rapid assessment within 3 hours; give antibiotics if concern persists | Conditional |
| Low likelihood of infection, no shock | Defer antibiotics, monitor closely | Conditional |
| Prehospital (EMS >60 min transport) with definite/probable septic shock | Give antibiotics in ambulance or flight | Conditional (new) |
Antibiotic Selection & Stewardship
| # | Recommendation | Strength |
|---|---|---|
| 22 | Use clinical evaluation alone (not procalcitonin) to decide whether to start antibiotics | Conditional |
| 25/26 | Use empiric MDR coverage only if high risk for MDR pathogen; avoid if low risk | Conditional (new) |
| 27 | Against routine empiric antifungal therapy; consider case-by-case in high-risk | Conditional (revisited) |
| 28/29 | Empiric anaerobic coverage only when specific risk factors present (intra-abdominal, necrotizing soft tissue, head/neck, CNS abscess) | Conditional (new) |
| 33 | Prolonged infusion of beta-lactams (extended or continuous) over bolus | Strong (upgraded — high certainty, BLING III trial) |
| 34 | TDM of antimicrobials on case-by-case basis | Conditional |
| 36 | De-escalate antibiotics when confirmed microbiological diagnosis available | Strong |
| 37 | De-escalate when no pathogens identified on final cultures | Conditional |
| 39 | Use shorter antibiotic durations (BALANCE trial supports 7 vs 14 days) | Conditional |
| 40 | Use procalcitonin + clinical evaluation to guide discontinuation | Conditional |
| 41 | SDD (selective decontamination of digestive tract) in mechanically ventilated patients in low MDR prevalence units | Conditional (new) |
Source Control
| # | Recommendation |
|---|---|
| 23 | Rapidly evaluate for anatomical sources requiring emergent source control (Good Practice) |
| 24 | Early source control, ideally within 6 hours |
Hemodynamic Management
Fluids
| # | Recommendation | Strength |
|---|---|---|
| 43 | Crystalloids as first-line | Strong |
| 44 | Balanced crystalloids over 0.9% saline (except traumatic brain injury — use saline) | Conditional (upgraded) |
| 45 | Crystalloids alone over crystalloids + albumin; albumin may be appropriate if large crystalloid volumes given or cirrhosis | Conditional (revised) |
| 46 | Against starches | Strong |
| 47 | Against gelatins | Conditional |
| 48 | After 30 mL/kg, either liberal or restrictive strategy is acceptable — individualize | Conditional |
| 49 | Use dynamic measures (PLR, SV, SVV, PPV) over static measures to guide ongoing resuscitation | Conditional |
| 89 | After acute resuscitation phase, use active fluid removal (diuretics ± ultrafiltration) | Conditional (new) |
Vasopressors
| # | Recommendation | Strength |
|---|---|---|
| 53 | Norepinephrine first-line over dopamine, epinephrine, selepressin | Strong |
| 54 | Against terlipressin | Conditional |
| 55 | Norepinephrine preferred over vasopressin or angiotensin II as first-line | Conditional |
| 56 | Add vasopressin when escalating norepinephrine doses | Conditional |
| 57 | Add epinephrine if MAP inadequate despite norepinephrine + vasopressin | Conditional |
| 58 | In septic shock with cardiac dysfunction: use either norepinephrine or epinephrine | Conditional (new) |
| 59 | Methylene blue: insufficient evidence for or against in refractory shock | — |
| 60/61 | For septic shock + cardiac dysfunction + persistent hypoperfusion: use inotropes (dobutamine or epinephrine) in addition to vasopressors | Conditional |
| 62 | Against levosimendan | Conditional |
| 64 | Against beta-blockers for treatment of septic shock | Conditional (new) |
Monitoring
| # | Recommendation |
|---|---|
| 42 | Either invasive or non-invasive BP monitoring acceptable; invasive preferred with high-dose/escalating vasopressors |
| 51 | Use serial lactate measurements to guide resuscitation; individualize fluid after initial bolus rather than targeting lactate normalization |
| 52 | Use capillary refill time as adjunct to other perfusion measures |
Respiratory Support
| # | Recommendation | Strength |
|---|---|---|
| 65 | Measure oxygenation by SpO₂ or ABG + clinical assessment | Conditional (new) |
| 66 | Titrate FiO₂ to either liberal (~SpO₂ ≥96%) or conservative (~90–93%) targets depending on patient factors | Conditional (new) |
| 67 | HFNC over conventional oxygen for PaO₂/FiO₂ <200 | Conditional (new) |
| 68 | HFNC over NIPPV as initial therapy | Conditional (new) |
| 69 | HFNC over alternating HFNC + NIPPV | Conditional (new) |
| 70 | Trial of awake proning in non-intubated patients | Conditional (new) |
| 71 | Low tidal volume 6 mL/kg IBW for ARDS | Strong (carryover) |
| 72 | For sepsis-induced respiratory failure without ARDS: tidal volume 6–8 mL/kg IBW | Conditional (new) |
| 73 | Plateau pressure ≤30 cmH₂O for ARDS | Strong |
| 74 | Higher PEEP for moderate-severe ARDS | Conditional |
| 75 | Against incremental PEEP titration strategy | Strong |
| 76 | Prone ventilation >12 hours daily for moderate-severe ARDS | Conditional |
| 77 | Intermittent NMBA boluses over continuous infusion | Conditional |
| 78 | VV-ECMO for severe ARDS when conventional ventilation fails (experienced centers) | Conditional |
Adjunctive & Additional Therapies
| # | Therapy | Recommendation |
|---|---|---|
| 79 | IV corticosteroids in septic shock | Conditional (revisited — broader indication, no longer requiring vasopressor-dependence explicitly) |
| 80 | Against antipyretics (pharmacologic or cooling) for improving outcomes | Conditional (new) |
| 81 | Against IV vitamin C | Conditional |
| 82 | Against IV immunoglobulin | Conditional |
| 83 | Against blood purification (hemoperfusion, hemofiltration, plasma exchange) | Conditional |
| 84 | Against polymyxin B hemoperfusion | Conditional |
| 85 | Against vitamin D therapy for sepsis | Conditional (new) |
| 87 | Stress ulcer prophylaxis with PPIs in patients with GI bleeding risk factors | Conditional |
| 88 | Against probiotics | Conditional (new) |
| 90 | Restrictive transfusion strategy (Hb threshold ~7 g/dL) | Strong |
| 91 | Early enteral nutrition within 72 hours | Conditional |
| 92 | Start insulin at glucose ≥180 mg/dL (10 mmol/L) | Strong |
| 93 | Against RRT without definitive indication for AKI | Conditional |
| 94 | Either continuous or intermittent RRT when warranted | Conditional |
| 95 | Against sodium bicarbonate to improve hemodynamics | Conditional |
| 96 | Sodium bicarbonate for pH ≤7.2 + AKI (AKIN 2–3) | Conditional |
| 97/98 | Pharmacologic VTE prophylaxis (LMWH preferred over UFH) | Strong |
Corticosteroids (2026 update): The recommendation was revised — the panel now suggests IV corticosteroids for septic shock broadly (conditional, low certainty), not limited to refractory vasopressor dependence. Hydrocortisone 200 mg/day is the practical dose used by 90% of panelists.
Goals of Care, Transitions, & Long-Term Outcomes
| Domain | Key Points |
|---|---|
| Goals of care | Discuss early (within 72 h); clinician-driven palliative care preferred over routine formal palliative care consultation |
| Advanced directives | Health systems should ensure discharge patients can execute directives; insufficient evidence to mandate systematic establishment |
| Transitions | Use critical care transition programs; pharmacist-led medication reconciliation |
| Post-hospital follow-up | Offer post–critical illness follow-up services for physical, cognitive, and mental health |
| Physical rehab | Offer physical rehabilitation after discharge (especially if ventilated >48 h) |
| Mental health | Offer mental health support; refer those with symptoms for formal evaluation |
| Cognition | Insufficient evidence for specific cognition-targeted therapies |
Key Changes from SSC 2021
| Topic | 2021 | 2026 |
|---|---|---|
| Screening tool in hospital | Against qSOFA alone | NEWS/NEWS2/MEWS/SIRS over qSOFA (stronger, upgraded) |
| MAP target in elderly | MAP ≥65 mmHg | MAP 60–65 mmHg for ≥65 years (new) |
| Beta-lactam infusion | Suggested prolonged infusion | Strong recommendation for prolonged infusion (BLING III) |
| Corticosteroids | Vasopressor-dependent shock | Septic shock broadly (conditional) |
| Fluid type | Balanced crystalloids suggested | Evidence strengthened (moderate certainty) |
| Albumin | Suggest in large-volume resuscitation | Suggest crystalloids alone; albumin for cirrhosis/large volumes |
| Prehospital antibiotics | Not addressed | Suggested if >60 min to hospital evaluation and septic shock |
| HFNC | Suggested over conventional O₂ | Full new hierarchy: HFNC > NIPPV > conventional O₂ |
| Awake proning | Not addressed | Suggested in non-intubated patients (new) |
| SDD | Not addressed | Suggested in low-MDR settings (new) |
| Antipyretics | Not addressed | Against using for outcome improvement (new) |
| Vitamin D | Not addressed | Against (new) |
| Probiotics | Not addressed | Against (new) |
| Active fluid removal | Not addressed | Suggested post-resuscitation (new) |
| Beta-blockers | Not addressed | Against (new) |
Source: Prescott HC, Antonelli M, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026. Intensive Care Med. Published online 23 March 2026. DOI: 10.1007/s00134-026-08361-1
This is a shared conversation. Sign in to Orris to start your own chat.